Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, Capital Increase in Genmab as a Result of Execution of Private Placement to GlaxoSmithKline7 Feb 2007
InvestorService: Genmab, to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference5 Feb 2007
Genmab, Global Agreement for HuMax-CD20 Receives Antitrust Clearance5 Feb 2007
Genmab, Announces Change in Board of Directors31 Jan 2007
Genmab, notification from major shareholder (section 29) from Ares Trading A/S18 Jan 2007
Genmab, notification from major shareholder (section 29) from Serono B.V. - Correction18 Jan 2007
Genmab, notification from major shareholder (section 29) from Fidelity15 Jan 2007
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
Genmab, articles of association on December 13, 20063 Jan 2007
Genmab, Financial Calendar for 20072 Jan 2007
Genmab, GlaxoSmithKline and Genmab Enter Global Agreement for HuMax-CD2019 Dec 2006
Genmab, Announcement of Additional Details Concerning the Issue of Shares to GlaxoSmithKline19 Dec 2006
InvestorService: Genmab, Announces AMG 714 Development Update15 Dec 2006
  • Previous
  • 1
  • More pages
  • 122
  • 123
  • 124
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863